Prophase Labs IncNASDAQ:PRPHNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7224
- TODAY'S CHANGE (%)-0.0221 (-2.9684%)
- Bid / Lots0.7161/ 13
- Ask / Lots0.7299/ 6
- Open / Previous Close0.7400 / 0.7445
- Day Range
- 52 Week Range
- Volume86,415
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRPH |
|---|---|---|
| 09:32 ET | 1779 | 0.74 |
| 09:46 ET | 600 | 0.74505 |
| 09:51 ET | 100 | 0.749 |
| 10:00 ET | 5000 | 0.749699 |
| 10:06 ET | 5197 | 0.7497 |
| 10:09 ET | 330 | 0.7497 |
| 10:11 ET | 2250 | 0.7497 |
| 10:13 ET | 300 | 0.7402 |
| 10:15 ET | 750 | 0.744149 |
| 10:18 ET | 5106 | 0.74 |
| 10:20 ET | 1238 | 0.74 |
| 10:22 ET | 600 | 0.74405 |
| 10:27 ET | 2000 | 0.74405 |
| 10:29 ET | 500 | 0.74 |
| 10:31 ET | 13159 | 0.7338 |
| 10:33 ET | 8050 | 0.720301 |
| 10:38 ET | 5000 | 0.72 |
| 10:40 ET | 100 | 0.749 |
| 10:44 ET | 956 | 0.72 |
| 10:47 ET | 1500 | 0.7201 |
| 11:03 ET | 100 | 0.73 |
| 11:05 ET | 905 | 0.73 |
| 11:20 ET | 402 | 0.749 |
| 11:36 ET | 100 | 0.748 |
| 12:03 ET | 5100 | 0.736 |
| 12:12 ET | 4413 | 0.723 |
| 12:15 ET | 4320 | 0.723 |
| 12:26 ET | 1200 | 0.72 |
| 12:46 ET | 300 | 0.748899 |
| 12:51 ET | 100 | 0.748 |
| 12:53 ET | 1000 | 0.724101 |
| 01:02 ET | 1500 | 0.724 |
| 01:18 ET | 100 | 0.749 |
| 01:29 ET | 100 | 0.749 |
| 01:58 ET | 100 | 0.749 |
| 02:21 ET | 100 | 0.749 |
| 02:23 ET | 1500 | 0.7395 |
| 02:32 ET | 981 | 0.7489 |
| 02:45 ET | 100 | 0.749 |
| 02:50 ET | 1000 | 0.748999 |
| 02:52 ET | 3439 | 0.73 |
| 02:54 ET | 661 | 0.7241 |
| 03:06 ET | 1500 | 0.72 |
| 03:08 ET | 256 | 0.7263 |
| 03:17 ET | 500 | 0.714542 |
| 03:24 ET | 453 | 0.7224 |
Nov 19, 2024
Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision, from 8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 13, 2024
ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones*DJ ProPhase Labs 3Q Loss/Shr 35c >PRPH, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
ProPhase Labs Announces Closing of Public Offering of Common Stock, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 11, 2024
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024, from 9:52AM ET on Monday Nov 11, 2024 by Dow Jones
9:52AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Prophase Labs Inc | 18.4M | -0.5x | --- |
Interpace Biosciences Inc | 11.7M | 2.7x | --- |
Global Cord Blood Corp | 167.4M | 2.2x | +20.97% |
Psychemedics Corp | 13.8M | -4.6x | --- |
Streamline Health Solutions Inc | 13.3M | -9.3x | --- |
Selectis Health Inc | 5.2M | -0.9x | --- |
Company Information
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Contact Information
- Headquarters
- 711 STEWART AVE, SUITE 200, GARDEN CITYNEW YORK, NY, United States 11530
- Phone
- 215-345-0919
- Fax
- ---
Executives
- Director
- Ted Karkus
- Chief Operating Officer
- Jed Latkin
- Independent Director
- Jason Barr
- Independent Director
- Louis Gleckel
- Independent Director
- Warren Hirsch
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.4M |
|---|---|
Revenue (TTM) | $12.8M |
Shares Outstanding | 23.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.29 |
EPS | $-1.50 |
Book Value | $2.74 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -277.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
